Sign In
Buy ARDX
$6.18
-0.190 (-2.98%)
At Close: Jun 23, 2026
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
09:34am, Thursday, 14'th Nov 2024
Ardelyx's Q3 revenue grew to $98 million, with strong Xphozah sales despite CMS's recent bundling ruling impacting future reimbursement. The CMS lawsuit dismissal affected Xphozah's reimbursement pros
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
12:31pm, Friday, 08'th Nov 2024
Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients' health at risk Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis pat
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
08:00am, Tuesday, 05'th Nov 2024
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript
11:20pm, Thursday, 31'st Oct 2024
Ardelyx, Inc. (NASDAQ:ARDX ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael R
Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics
06:31pm, Thursday, 31'st Oct 2024
The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
06:20pm, Thursday, 31'st Oct 2024
Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.03 per share a year ago.
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
04:02pm, Thursday, 31'st Oct 2024
IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million
Ninety percent of survey participants reported “some” or “significant” negative impact of IBS-C on their life Survey results presented in two poster presentations WALTHAM, Mass., Oct. 28, 2024
Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline
11:05am, Thursday, 24'th Oct 2024
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ardelyx, Inc. (NASDAQ: ARDX) on
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
04:05pm, Tuesday, 22'nd Oct 2024
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher
10:56am, Friday, 18'th Oct 2024
After losing some value lately, a hammer chart pattern has been formed for Ardelyx (ARDX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
08:00am, Thursday, 17'th Oct 2024
WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
04:30pm, Tuesday, 15'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, fol
Ardelyx, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX
11:15am, Tuesday, 15'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, fol
